Treatment With Eribulin Mesylate in Metastatic Breast Cancer
3 Views
administrator
07/03/23
In this segment, panelists explore the cytotoxic agent eribulin mesylate, which has been the focus of several recent clinical trials. In all, despite a growing focus on targeted therapies, cytotoxics remain an important class of drugs in the treatment of patients with metastatic breast cancer.
To view more from this discussion, visit http://www.onclive.com/peer-ex....change/MBC-challenge
-
Category
Show more
Facebook Comments
No comments found